Item 5.07 Submission of Matters to a Vote of Security Holders.

On August 10, 2022, VYNE Therapeutics Inc. (the "Company") held its 2022 Annual Meeting of Stockholders (the "Annual Meeting"). At the Annual Meeting, the Company's stockholders voted on four proposals, each of which is described in more detail in the Company's definitive proxy statement filed with the Securities and Exchange Commission on June 17, 2022. Only stockholders of record as of the close of business on June 14, 2022, the record date for the Annual Meeting, were entitled to vote at the Annual Meeting. Of the 57,975,162 shares outstanding as of the record date, 29,500,152, or approximately 51%, were present or represented by proxy at the Annual Meeting, representing a quorum. The following is a summary of the matters voted on at the Annual Meeting.

Proposal 1. The stockholders elected the following three directors to the Company's Board of Directors, to hold office until the 2025 annual meeting of stockholders or until their respective successors are elected. The voting results were as follows:





                                    Votes
     Nominee         Votes For    Withheld    Broker Non-Votes
Steven Basta         12,846,639   2,777,584      13,875,929
Anthony Bruno        12,887,609   2,736,614      13,875,929
Elisabeth Sandoval   12,909,448   2,714,775      13,875,929

Proposal 2. The stockholders ratified the appointment of Baker Tilly U.S. LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2022. The voting results were as follows:





Votes For    Votes Against   Abstentions
27,154,794     1,643,633       701,725

Proposal 3. The stockholders did not approve an amendment to the Company's Amended and Restated Certificate of Incorporation to effect a reverse stock split of the Company's common stock at a ratio ranging from 1-for-5 shares up to a ratio of 1-for-15 shares. Approval of this proposal required the affirmative vote of a majority of the total shares outstanding as of the record date. The voting results were as follows:





Votes For    Votes Against   Abstentions
23,723,797     5,505,372       270,983

Proposal 4. The stockholders approved management's ability to adjourn the Annual Meeting to a later date or dates, if necessary or appropriate, to solicit additional proxies if there were insufficient votes to adopt Proposal 3. The voting results were as follows:





Votes For    Votes Against   Abstentions
24,466,143     4,658,386       375,623


Item 8.01 Other Events.

On August 10, 2022, the Company issued a press release entitled "VYNE Therapeutics Announces Results from its Phase 2a Trial of FMX114 for the Treatment of Mild-to-Moderate Atopic Dermatitis." A copy of the press release is attached as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated by reference herein.

Item 9.01. Financial Statements and Exhibits.





(d) Exhibits

The following exhibit is being filed herewith.

Exhibit No. Description

99.1 Press Release, dated August 10, 2022.

104 Cover Page Interactive Data File (embedded within the Inline XBRL document)

© Edgar Online, source Glimpses